ARS Pharmaceuticals, Inc
$ 6.16
10.99%
07 Aug - close price
- Market Cap 611,708,000 USD
- Current Price $ 6.16
- High / Low $ 6.16 / 5.58
- Stock P/E N/A
- Book Value 0.62
- EPS -2.00
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -1.36 %
- 52 Week High 17.54
- 52 Week Low 4.91
About
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Analyst Target Price
$26.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-09 | 2025-11-10 | 2025-08-13 | 2025-05-14 | 2025-03-20 | 2024-11-13 | 2024-08-06 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.61 | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 | -0.2 | -0.13 | -0.11 | -0.07 | -0.16 | -0.18 |
| Estimated EPS | -0.53 | -0.4246 | -0.49 | -0.51 | -0.36 | -0.1175 | -0.14 | -0.11 | -0.11 | -0.14 | -0.18 | -0.16 |
| Surprise | -0.08 | 0.0046 | -0.03 | 0.05 | 0.01 | 0.6275 | -0.06 | -0.02 | 0 | 0.07 | 0.02 | -0.02 |
| Surprise Percentage | -15.0943% | 1.0834% | -6.1224% | 9.8039% | 2.7778% | 534.0426% | -42.8571% | -18.1818% | 0% | 50% | 11.1111% | -12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.55 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SPRY
2026-08-07 01:12:22
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who wish to serve as lead plaintiff must move the Court by October 5, 2026.
2026-08-06 22:12:22
The Rosen Law Firm has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Shareholders who suffered losses are urged to contact the firm by October 5, 2026, to serve as lead plaintiff.
2026-08-06 18:45:00
SueWallSt is alerting investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a securities class action lawsuit, with a lead plaintiff deadline of October 5, 2026. The lawsuit stems from a 23.9% stock decline after ARS Pharmaceuticals announced that CVS Caremark had postponed its formulary decision for neffy until January 2027, contrary to earlier analyst expectations for a July 1, 2026 coverage. The complaint alleges that ARS's public statements did not adequately disclose the risk of this delay, leading to inflated stock prices.
2026-08-06 16:11:09
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by Holzer & Holzer, LLC, alleging the company made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. Investors who purchased ARS shares between March 9, 2026, and June 24, 2026, and incurred losses are encouraged to contact the law firm to discuss their legal rights, with a deadline of October 5, 2026, to be appointed lead plaintiff. Holzer & Holzer, LLC specializes in securities litigation and has a history of recovering funds for shareholders.
2026-08-06 12:13:00
Faruqi & Faruqi, LLP reminds investors in ARS Pharmaceuticals (NASDAQ: SPRY) of the October 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expected timeline for expanded insurance coverage of neffy through CVS Caremark, which led to a significant stock price drop. Investors who purchased ARS Pharmaceuticals securities between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their legal options.
2026-08-06 02:42:24
Robbins LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. The company's stock price dropped significantly after it announced that the expected July 1, 2026, coverage would not materialize, causing substantial losses for investors.
